Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 510 versus docetaxel in previously treated KRAS G12C-mutated NSCLC
NL-OMON56228Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing AMG 510 with docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Jun 2020; status: active, not recruiting.
02
Drugs
sotorasibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56228.